Related Experiment Video

Updated: Jun 30, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

[Progress in small-molecule inhibitors of Bcl-2 family proteins]

Yong Tang1, Da-yong Zhang, Xiao-ming Wu

  • 1School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|September 30, 2008
PubMed

Insights

Apoptosis, crucial for organism homeostasis, is regulated by Bcl-2 family proteins. Small molecule inhibitors targeting these proteins show promise for cancer therapy, as reviewed from a drug design perspective.

Area of Science:

  • Cellular biology
  • Molecular biology
  • Biochemistry

Background:

  • Apoptosis is vital for maintaining organism homeostasis.
  • Bcl-2 family proteins, including anti-apoptotic (e.g., Bcl-2, Bcl-xL) and pro-apoptotic members, are key regulators of apoptosis.
  • Overexpression of anti-apoptotic Bcl-2 proteins is common in human cancers, disrupting normal cell death pathways.

Purpose of the Study:

  • To review the progress in developing small molecule inhibitors of Bcl-2 family proteins.
  • To provide insights into drug design strategies targeting these key apoptosis regulators.

Main Methods:

  • Review of recent scientific literature on Bcl-2 family protein structures and inhibitor development.
  • Analysis of drug design approaches based on structural information.

Main Results:

  • Small molecule inhibitors targeting Bcl-2 family proteins have been developed.
  • Structural insights have guided the design of these inhibitors.

Conclusions:

  • Targeting Bcl-2 family proteins with small molecule inhibitors is a promising strategy for cancer therapy.
  • Continued research in drug design holds potential for developing effective anti-cancer agents.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...